Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIA Study
2018-001438-16Phase 3Active
- Sponsor
- OBI Pharma
- Start
- Sep 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adagloxad simolenin in triple-negative breast cancer (TNBC) (2 arms), sponsored by OBI Pharma. Primary endpoint: Invasive disease-free survival. Started Sep 2021; status: active.
02
Drugs
adagloxad simolenin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2018-001438-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001438-16.